Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
NCT04772079Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2021
- Primary completion
- Jan 2029
- Countries
- 13
01
Overview
A Phase 3 trial of deucravacitinib in plaque psoriasis, sponsored by Bristol Myers Squibb. Started Mar 2021; status: recruiting.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04772079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04772079.